(Q39496556)

12 September 2017

Response to third-line endocrine treatment for advanced breast cancer (English)

1 reference

12 September 2017

Iveson TJ

1

1 reference

PubMed ID

8435212

12 September 2017

Ahern J

series ordinal

2

1 reference

PubMed ID

8435212

12 September 2017

Smith IE

series ordinal

3

1 reference

12 September 2017

1 January 1993

1 reference

European Journal of Cancer

12 September 2017

1 reference

12 September 2017

29A

1 reference

12 September 2017

4

1 reference

12 September 2017

572-574

1 reference

Additive hormonal therapy in women with advanced breast cancer

12 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980154-6

7 January 2021

Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980154-6

7 January 2021

Suppression of estrogens with Aminoglutethimide and hydrocortisone (medical adrenalectomy) as treatment of advanced breast carcinoma: A review

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980154-6

7 January 2021

Low dose aminoglutethimide without hydrocortisone for the treatment of advanced postmenopausal breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980154-6

7 January 2021

Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980154-6

7 January 2021

Norethisterone acetate as secondary endocrine treatment in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980154-6

7 January 2021

Megestrol acetate versus aminoglutethimide for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980154-6

7 January 2021

Randomized trial comparing aminoglutethimide with high-dose medroxyprogesterone acetate in therapy for advanced breast carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980154-6

7 January 2021

Aromatase inhibitors in the treatment of advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980154-6

7 January 2021

LHRH analogues in the treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980154-6

7 January 2021

Oral high-dose progestins as treatment for advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980154-6

7 January 2021

Androgen-induced remissions after antiestrogen and hypophysectomy in stage IV breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980154-6

7 January 2021

Therapeutic oophorectomy in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980154-6

7 January 2021

The definition of the ‘no change’ category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980154-6

7 January 2021

10.1016/S0959-8049(05)80154-6

Identifiers

DOI

1 reference

12 September 2017

1 reference

PubMed ID

8435212